A-56619、A-56620、阿米氟沙星、环丙沙星、依诺沙星、诺氟沙星和氧氟沙星对耐甲氧西林金黄色葡萄球菌的体外比较
In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus.
作者信息
Smith S M
出版信息
Antimicrob Agents Chemother. 1986 Feb;29(2):325-6. doi: 10.1128/AAC.29.2.325.
Abstract
Seven quinolone antibiotics were tested against 115 isolates of methicillin-resistant Staphylococcus aureus. The MICs for 90% of the strains tested were 0.5 microgram/ml for A-56619, A-56620, ciprofloxacin, and ofloxacin; 2.0 micrograms/ml for amifloxacin and enoxacin; and 4.0 micrograms/ml for norfloxacin. Killing kinetic studies showed a similar killing rate for all seven antibiotics.
摘要
对115株耐甲氧西林金黄色葡萄球菌菌株测试了七种喹诺酮类抗生素。对于所测试的90%的菌株，A-56619、A-56620、环丙沙星和氧氟沙星的最低抑菌浓度（MIC）为0.5微克/毫升；阿米氟沙星和依诺沙星为2.0微克/毫升；诺氟沙星为4.0微克/毫升。杀菌动力学研究表明，所有七种抗生素的杀菌速率相似。
相似文献
1
In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 1986 Feb;29(2):325-6. doi: 10.1128/AAC.29.2.325.
2
Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
J Antimicrob Chemother. 1986 May;17(5):623-8. doi: 10.1093/jac/17.5.623.
3
Comparative in vitro activity of amifloxacin and five other fluoroquinolone antimicrobial agents and preliminary criteria for the disk susceptibility test.
Eur J Clin Microbiol. 1987 Apr;6(2):179-82. doi: 10.1007/BF02018204.
4
In vitro evaluation of A-56619 and A-56620, two new quinolones.
Antimicrob Agents Chemother. 1986 Jan;29(1):40-3. doi: 10.1128/AAC.29.1.40.
5
Comparative in vitro activity of seven quinolones against 100 clinical isolates of Clostridium difficile.
Antimicrob Agents Chemother. 1986 Feb;29(2):374-5. doi: 10.1128/AAC.29.2.374.
6
Comparative in vitro activities of pefloxacin, ofloxacin, enoxacin and ciprofloxacin against 256 clinical isolates.
Acta Pathol Microbiol Immunol Scand B. 1987 Apr;95(2):141-6. doi: 10.1111/j.1699-0463.1987.tb03102.x.
7
Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone.
J Antimicrob Chemother. 1987 Sep;20(3):363-72. doi: 10.1093/jac/20.3.363.
8
Comparison of in vitro activity of quinolone antibiotics and vancomycin against gentamicin- and methicillin-resistant Staphylococcus aureus by time-kill kinetic studies.
Antimicrob Agents Chemother. 1986 Dec;30(6):823-7. doi: 10.1128/AAC.30.6.823.
9
In vitro susceptibility of aerobic gram-negative blood culture isolates to oxolinic acid, norfloxacin, ciprofloxacin, enoxacin, pefloxacin, ofloxacin and oxo-enoxacin.
Infection. 1986 May-Jun;14(3):142-4. doi: 10.1007/BF01643481.
10
Activity of nadifloxacin against methicillin-resistant Staphylococcus aureus isolated from skin infections: comparative study with seven other fluoroquinolones.
J Int Med Res. 1996 Jan-Feb;24(1):12-6. doi: 10.1177/030006059602400102.
引用本文的文献
1
Clinical importance and epidemiology of quinolone resistance.
Infect Chemother. 2014 Dec;46(4):226-38. doi: 10.3947/ic.2014.46.4.226. Epub 2014 Dec 29.
2
Whole animal automated platform for drug discovery against multi-drug resistant Staphylococcus aureus.
PLoS One. 2014 Feb 19;9(2):e89189. doi: 10.1371/journal.pone.0089189. eCollection 2014.
3
Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
Antimicrob Agents Chemother. 2009 May;53(5):2074-81. doi: 10.1128/AAC.01056-08. Epub 2009 Feb 17.
4
Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections.
Drugs. 1996 Jan;51(1):137-60. doi: 10.2165/00003495-199651010-00009.
5
In vitro susceptibilities of rapidly growing mycobacteria to newer antimicrobial agents.
Antimicrob Agents Chemother. 1994 Jan;38(1):134-7. doi: 10.1128/AAC.38.1.134.
6
Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis.
Antimicrob Agents Chemother. 1987 Apr;31(4):527-30. doi: 10.1128/AAC.31.4.527.
7
Comparison of in vitro activity of quinolone antibiotics and vancomycin against gentamicin- and methicillin-resistant Staphylococcus aureus by time-kill kinetic studies.
Antimicrob Agents Chemother. 1986 Dec;30(6):823-7. doi: 10.1128/AAC.30.6.823.
8
Comparative evaluation of identification systems for testing methicillin-resistant strains of Staphylococcus aureus.
J Clin Microbiol. 1986 Aug;24(2):173-6. doi: 10.1128/jcm.24.2.173-176.1986.
9
Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Drugs. 1987 Apr;33(4):346-91. doi: 10.2165/00003495-198733040-00003.
10
Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Drugs. 1988 Apr;35(4):373-447. doi: 10.2165/00003495-198835040-00003.
本文引用的文献
1
The emergence of methicillin-resistant Staphylococcus aureus.
Ann Intern Med. 1982 Sep;97(3):440-2. doi: 10.7326/0003-4819-97-3-440.
2
Treatment of infections due to methicillin-resistant Staphylococcus aureus.
Ann Intern Med. 1982 Sep;97(3):376-8. doi: 10.7326/0003-4819-97-3-376.
3
Community-acquired methicillin-resistant Staphylococcus aureus infections: a new source for nosocomial outbreaks.
Ann Intern Med. 1982 Sep;97(3):325-9. doi: 10.7326/0003-4819-97-3-325.
4
Multiply antibiotic-resistant Staphylococcus aureus: introduction, transmission, and evolution of nosocomial infection.
Ann Intern Med. 1982 Sep;97(3):317-24. doi: 10.7326/0003-4819-97-3-317.
5
In vitro and in vivo activity of DL-8280, a new oxazine derivative.
Antimicrob Agents Chemother. 1982 Oct;22(4):548-53. doi: 10.1128/AAC.22.4.548.
6
In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid.
Antimicrob Agents Chemother. 1983 May;23(5):641-8. doi: 10.1128/AAC.23.5.641.
7
Antimicrobial spectrum of Win 49375.
Antimicrob Agents Chemother. 1984 Jul;26(1):104-7. doi: 10.1128/AAC.26.1.104.
8
In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.
Antimicrob Agents Chemother. 1983 Nov;24(5):754-63. doi: 10.1128/AAC.24.5.754.
9
In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.
Eur J Clin Microbiol. 1983 Apr;2(2):111-5. doi: 10.1007/BF02001575.
10
Enoxacin compared with cefoperazone for the treatment of experimental Enterobacter aerogenes endocarditis.
Antimicrob Agents Chemother. 1985 May;27(5):708-11. doi: 10.1128/AAC.27.5.708.
Zotero 插件